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Summary We report an autopsy case showing medial necrosis at the segment of
sirolimus-eluting stent implantation. These ﬁndings indicate that cytotoxic effects of
sirolimus can induce late-acquired incomplete stent apposition and/or aneurysmal
changes after stenting in human coronary arteries.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Introduction
Sirolimus-eluting stents (SESs) have been proven
to reduce the rate of restenosis by a striking
inhibition of neointimal hyperplasia [1]. However,
unusual vessel responses to SES, such as late-
acquired incomplete stent apposition (ISA), have
been observed on follow-up intravascular ultra-
sound (IVUS) in patients who received SES [2,3].
Although the precise mechanism of late ISA has not
been clariﬁed, focal positive vessel remodeling is
thought to be a potent candidate. It was reported
that exposure to a high dose of paclitaxel elimi-
nated direct contact between the strut sites and
medial wall by medial wall cell necrosis, imply-
ing that the vessel wall had undergone dilatation
relative to the stent in a porcine model [4].
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ase report
65-year-old man with effort angina for more than
months was admitted to our hospital. His risk
actor was uncontrolled diabetes mellitus. Coro-
ary angiography showed total occlusion of the
roximal right coronary artery (RCA) (Fig. 1A). On
pril 4, 2005, he received a sirolimus-eluting stent
SES) (Cypher, Cordis Corporation, Miami Lakes,
L) to treat this lesion. The RCA was crossed by
0.0014 in. Neos Intermediate wire (Asahi Intecc
orporation, Aichi) with Excelsior (Boston Scien-
iﬁc, Natic, MA) using 7 FR JR4 Launcher GUIDING
ATHETER (Medtronic, Minneapolis, MN). Then, the
esion was opened with a 2.5mm× 30mm-long
yujin Plus balloon catheter (Terumo Corpora-
gy. Published by Elsevier Ireland Ltd. All rights reserved.
Medial necrosis by sirolimus-eluting stent 61
F cclu
( ance
s gniﬁ
t
a
d
a
a
d
c
w
p
c
a
o
b
t
i
s
m
s
a
r
r
m
t
w
a
s
s
t
S
s
p
t
b
r
c
p
D
T
t
rigure 1 Angiograms of the RCA showing chronic total o
B, arrows). Right panels (C and D): macroscopic appear
howed only minimal neointimal formation (D, higher ma
ion, Tokyo) inﬂated to 8 atm. After predilatation,
single SES (3.0mm× 30mm) was successfully
eployed at 22 atm (Fig. 1B). The patient remained
symptomatic after stenting on ticlopidine (200mg)
nd aspirin (100mg), but died of severe acute sub-
ural hematoma on March 25, 2006.
Autopsy was performed after obtaining written
onsent from the patient’s family, and the heart
as ﬁxed in 10% buffered formalin. Details of the
athological procedures for examining the stented
oronary artery were previously described [5]. At
utopsy, the RCA SES was widely patent, and most
f the stented segment was still minimally covered
y neointima (Fig. 1C and D). Microscopically, a
hickened ﬁbrous plaque consisting of dense hyalin-
zed collagenous ﬁbers was present below the stent
truts at the culprit region (Fig. 2A and B). In
ost of the other portions, organizing ﬁbrin depo-
ition was observed around the struts (Fig. 3A
nd B), and despite almost complete coverage by
egenerating endothelial cells (ECs), the cellular
eaction by SMCs remained absent more than 11
onths after stenting (Fig. 3C and D). Mild neoin-
imal thickening (SMCs with extracellular matrix)
S
o
d
tsion (A, arrow) and immediately after SES implantation
of the specimen harvested 11.5 months after stenting
cation of the stented segment in C).
as observed around the circumference of lumen
t the stented site of atherosclerotic plaque-free
egments (Fig. 4A and B). In these regions, expan-
ion of the stent strut forced the struts contiguous
o the medial layer. Remarkable loss of medial
MCs was evident not only at the sites of the
tent struts that had contacted and focally com-
ressed the medial layer, but also the sites where
here was bowing of the media into the intima
etween the struts (Fig. 4C and D). Near-complete
e-endothelialization conﬁrmed by immunohisto-
hemical staining was clearly observed in these
ortions (Fig. 5A and B).
iscussion
wo noteworthy features regarding this case were
hat proliferation of the neointima covered by the
egenerated ECs was well inhibited and prominent
MC depletion of themedial wall was evident in part
f the SES implanted segment. In the present case,
epletion of medial SMCs was clearly observed at
he regions where compression of the media by the
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sFigure 2 Histological sections of a coronary segment w
magniﬁcation: A, 33.5×; B, 31.5×). Note thickened ﬁb
formation around the struts. Hematoxylin—eosin stain.
stent struts did not exist. Thus, it is possible that
these phenomena concerning elimination of medial
SMCs were elicited by not only mechanical injury
by stent expansion but also by the pharmacological
effect of sirolimus itself.
It has been demonstrated that stents coated with
a high dose of cytotoxic drugs such as paclitaxel
are able to induce medial necrosis in experimen-
tal animal studies [4,6]. However, it has also been
reported that SES inhibits stent-associated inﬂam-
mation and neointimal formation without medial
necrosis in the porcine coronary model [7]. To our
knowledge, this is the ﬁrst report of an implanted
SES causing depletion of medial SMCs in the human
coronary artery. Several lines of evidence have
demonstrated that sirolimus can induce apopto-
sis in medial SMCs [8,9]. However, as previously
described [4], the effect of SES observed in this case
might represent true necrosis of the medial wall,
with perhaps a smaller contribution from apopto-
sis. Furthermore, Virmani et al. [10] reported an
autopsy case that had shown aneurysmal dilata-
tion of the SES implanted arterial segments with
a severe localized hypersensitivity reaction to the
polymer consisting predominantly of T lymphocytes
and eosinophils. In the present case, however, we
i
T
a
wES implantation indicated by line a in Fig. 1D (original
plaque below the struts (*) and only mild neointimal
ould not observe such an obvious inﬂammatory
eaction in the portions with medial SMC depletion.
hus, it is suggested that the cytostatic effects of
irolimus on neointimal formation could be compli-
ated by these local cytotoxic effects followed by
decrease in arterial wall tension, causing stent
alapposition and/or aneurysmal change [11].
Interestingly, we observed that medial SMC
epletion was present only in the portions where
ES struts directly contacted the medial wall lay-
rs. The IVUS study investigating ISA portions also
howed that late-acquired ISA in SES was mainly
resent on the relatively disease-free side of the
essel wall [2]. From these data, we can deduce
hat diffusion of sirolimus from SES to the medial
ayer might be blocked if atherosclerotic plaques
re positioned between SES struts and the medial
ayer.
Despite the general acceptance that most cases
f ISA (acute or late) have a benign clinical
volution, impressive cases of ISA causing late
tent thrombosis followed by acute myocardial
nfarction have recently been reported [12,13].
hus, in view of the increased incidence of late-
cquired ISA in SES, careful long-term follow-up is
arranted.
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Figure 3 Histological sections of a coronary segment with SES implantation indicated by line b in Fig. 1D (original
magniﬁcation: 26.5×). Only a thin neointima with an organizing constituent of ﬁbrin was visible. Although ECs were
seen surrounding the lumen, there was no cellular reaction by SMCs around the struts (*) (C). The regenerated ECs of
the neointima (arrows) express von Willebrand factor (vWF) just like those of normal vasa vasorum (arrowheads) (D).
(A) Hematoxylin—eosin stain; (B) Masson’s trichrome stain. Immunostaining with anti-SMC-actin (C) and anti-vWF (D).
Figure 4 Histological sections of the plaque-free regions with SES implantation indicated by line c in Fig. 1C (orig-
inal magniﬁcations: A and B, 18.5×; C and D, 36.5×). Note remarkable depletion of medial SMCs (arrowheads) just
underneath the SES struts (*). (A) and (C) Hematoxylin—eosin stain. (B) and (D) SMC-actin stain.
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Figure 5 High power views of the same portion in
Fig. 4 (original magniﬁcation 75×). Immunohistochemical [
[
[staining of serial sections for CD34(A) and vWF(B) clearly
revealed the complete coverage of the luminal surface
by regenerated ECs (arrowheads). *Stent strut void.
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